https://www.pharmaradar360.com/article/a6d04440b8d67e7bPharmaRadar360en2026-04-10T00:00:00.000ZLatest Researchhttps://www.pharmaradar360.com/article/19f59684ccd74cc6PharmaRadar360en2026-04-10T00:00:00.000ZGeliose Mobility, an IIT Delhi incubated startup, launches ‘HOPE’, an affordable electric scooter for last mile delivery and personal commutehttps://www.pharmaradar360.com/article/78202b23746b7226PharmaRadar360en2026-04-09T21:17:00.000ZFoundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.https://www.pharmaradar360.com/article/a8a7c5178c0602f9PharmaRadar360en2026-04-09T20:25:00.000ZEmergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Programhttps://www.pharmaradar360.com/article/318faeabfec65a3fPharmaRadar360en2026-04-09T13:46:04.000ZViz.ai Earns Back-to-Back No. 1 Ranking in Black Book Survey of AI Clinical Decision Support Solutionshttps://www.pharmaradar360.com/article/0b087a04e25fccb2PharmaRadar360en2026-04-09T10:50:00.000ZLabcorp Declares Quarterly Dividendhttps://www.pharmaradar360.com/article/20920ccca3d25016PharmaRadar360en2026-04-09T10:45:00.000ZFoundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.https://www.pharmaradar360.com/article/42d7561a4d807d9dPharmaRadar360en2026-04-09T10:02:58.000ZZymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growthhttps://www.pharmaradar360.com/article/99984d5b127b95d4PharmaRadar360en2026-04-09T10:00:00.000ZTargeted therapy in early-stage classical Hodgkin lymphomahttps://www.pharmaradar360.com/article/d7cfe8927d4d3d9ePharmaRadar360en2026-04-09T07:00:00.000ZA simple model makes it possible to predict which patients experiencing a first psychotic episode will recover during the first yearhttps://www.pharmaradar360.com/article/788aa52547e7c5b1PharmaRadar360en2026-04-09T05:19:13.000ZNovartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030https://www.pharmaradar360.com/article/2e8d1dbea4fb5ecdPharmaRadar360en2026-04-09T02:00:00.000ZWhat plunged these chimps into civil war? A new study traces the breakdownhttps://www.pharmaradar360.com/article/8b2f5aca043fef73PharmaRadar360en2026-04-09T02:00:00.000ZRoaming gangs of tumor cells help spread cancer. Can drugs break them up?https://www.pharmaradar360.com/article/9a8cc9f87b8f7864PharmaRadar360en2026-04-09T02:00:00.000ZPharmac to fund two new combination treatments, and widen access to another, for people with a type of blood cancerhttps://www.pharmaradar360.com/article/93285d243cced900PharmaRadar360en2026-04-09T01:20:00.000ZDid quantum sensors help find a U.S. pilot shot down in Iran? Experts doubt ithttps://www.pharmaradar360.com/article/7be385973612f840PharmaRadar360en2026-04-09T00:00:00.000Z9 April 2026Departmental updateKazakhstan becomes first country in Central Asia to earn WHO recognition for regulation of medicines and imported vaccineshttps://www.pharmaradar360.com/article/8eef4f1fd11cab90PharmaRadar360en2026-04-09T00:00:00.000ZWhen Should I Get LASIK? Age, Eligibility, and Recovery Explainedhttps://www.pharmaradar360.com/article/cd0c881f416c0fadPharmaRadar360en2026-04-09T00:00:00.000ZOrion’s production processes in Turku, Finland to become carbon free with new steam plant4/9/2026 Sustainabilityhttps://www.pharmaradar360.com/article/b4bbfa2da4b2d23cPharmaRadar360en2026-04-09T00:00:00.000ZIntegrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancerhttps://www.pharmaradar360.com/article/558bc334ea005e9aPharmaRadar360en2026-04-09T00:00:00.000ZCD18-targeted peptide-drug conjugate remodels the immunosuppressive tumor microenvironment of prostate cancer by selective depletion of M2 macrophageshttps://www.pharmaradar360.com/article/7c1f870d3bcf76afPharmaRadar360en2026-04-09T00:00:00.000ZCardiometabolic and respiratory diseaseshttps://www.pharmaradar360.com/article/f962f98b2e2e660dPharmaRadar360en2026-04-09T00:00:00.000ZIdorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Developmenthttps://www.pharmaradar360.com/article/e0c28c2be852c373PharmaRadar360en2026-04-09T00:00:00.000Znews releases enhttps://www.pharmaradar360.com/article/ab64493bb687833fPharmaRadar360en2026-04-09T00:00:00.000ZImmunic to Participate in Scientific and Medical Conferences in Aprilhttps://www.pharmaradar360.com/article/03ef8f9a85223c81PharmaRadar360en2026-04-08T22:14:37.000ZBlaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contaminationhttps://www.pharmaradar360.com/article/194ed91c950cdccbPharmaRadar360en2026-04-08T22:00:00.000ZInvestor Access Event (Paris, France)https://www.pharmaradar360.com/article/9d1cf1d163d8a595PharmaRadar360en2026-04-08T21:18:56.000ZPatient Listening Session Summarieshttps://www.pharmaradar360.com/article/875a9550a96e7914PharmaRadar360en2026-04-08T20:09:24.000ZFDA approves safety labeling changes for opioid pain medicineshttps://www.pharmaradar360.com/article/991e22be9f881505PharmaRadar360en2026-04-08T20:09:03.000ZFDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chainhttps://www.pharmaradar360.com/article/bbb4a3a020ed9a96PharmaRadar360en2026-04-08T20:06:06.000ZFDA's ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neurosciencehttps://www.pharmaradar360.com/article/e7b337dbb00bb1d2PharmaRadar360en2026-04-08T20:05:23.000ZFDA revises letter of authorization for the emergency use authorization for Paxlovidhttps://www.pharmaradar360.com/article/4beffe81f1abf7ecPharmaRadar360en2026-04-08T19:57:52.000ZACRP Fellow Touts the Benefits of Bringing Clinical Research Stakeholders Togetherhttps://www.pharmaradar360.com/article/b68d421386b21a7ePharmaRadar360en2026-04-08T19:45:40.000ZFDA issues guidance regarding drug development for early Alzheimer’s diseasehttps://www.pharmaradar360.com/article/cfd198095cb7760cPharmaRadar360en2026-04-08T19:45:17.000ZFDA Announces New Quality Oversight Webpagehttps://www.pharmaradar360.com/article/c25e09efbeb1ebd7PharmaRadar360en2026-04-08T19:43:52.000ZFDA establishes CDER Center for Clinical Trial Innovation (C3TI)https://www.pharmaradar360.com/article/df9ea288dc0a278bPharmaRadar360en2026-04-08T19:41:22.000ZFDA issues agency-initiated proposed order regarding OTC monograph drugs containing acetaminophenhttps://www.pharmaradar360.com/article/083772a215c0308fPharmaRadar360en2026-04-08T19:40:48.000ZFDA updates guidance on interchangeabilityhttps://www.pharmaradar360.com/article/03e16993a733eb73PharmaRadar360en2026-04-08T19:39:19.000ZFDA's ISTAND Pilot Program accepts a submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury (DILI)https://www.pharmaradar360.com/article/ef48c2f3a79c78ccPharmaRadar360en2026-04-08T19:38:03.000ZFDA clarifies policies for compounders as national GLP-1 supply begins to stabilizehttps://www.pharmaradar360.com/article/502649853e56f8aePharmaRadar360en2026-04-08T19:37:25.000ZFDA approves REMS modification, advancing new drug disposal optionhttps://www.pharmaradar360.com/article/6b53c148356fbaf3PharmaRadar360en2026-04-08T18:30:54.167ZSigns You May Need a New Pillowhttps://www.pharmaradar360.com/article/e80c22b3a4bc5d28PharmaRadar360en2026-04-08T16:05:00.000ZAbbVie moves to close loopholes and strengthen accountability in 340B programhttps://www.pharmaradar360.com/article/55af2a71d1758243PharmaRadar360en2026-04-08T16:00:00.000ZUK formalizes zero tariffs deal with US, will pay more for drugs